已关闭
  • 顶部Banner位
  • 固定模块
设置
BPD
试用
AI
企业管理端
厂家
ITCH基因敲除细胞池(HCT116)
收藏 收藏
分享
原料试剂 研发实验室
价格
¥5499.00
品牌 粒曼生物
地区 中国,湖北省,武汉市
货号 LM01400078747
产地 国产
选择规格
1×10^6 cells/ 冻存管
易享客服
粒曼生物科技(武汉)有限公司
粒曼生物科技(武汉)有限公司
中国湖北武汉
营业执照已审核
粒曼生物专注于提供高通量细胞编辑解决方案,服务新药研发与基础科研。 粒曼生物是一家专注于高通量细胞编辑工具研发的技术驱动型公司,核心技术来自加州大学伯克利分校,公司已完成人全基因组19883个基因的敲除实验验证。基于粒曼工业智能化高通量体外细胞编辑平台,为客户提供基因敲除、过表达、点突变、原位/定点敲入定制服务及基因编辑细胞现货、基因敲除试剂盒等系列产品,助力新药研发与基础研究。 粒曼作为国内高通量基因敲除阵列文库领域的领导者,已建成自动化、高通量基因敲除平台,实现每月1000+ KO 细胞的生产产能。粒曼基于自身构建的 Harbor 细胞和 pCargo 质粒载体系统,实现 2 周高效构建稳定细胞系。
进入店铺
产品规格 图文详情 技术文档
产品规格
品牌名称
粒曼生物
货号
LM01400078747
国产/进口
国产
规格
1×10^6 cells/ 冻存管
货源
新品
图文详情

细胞基因敲除效率:88%

ITCH NCBI Gene ID:83737

ITCH Ensembl ID:ENSG00000078747

ITCH Uniprot ID:Q96J02

ITCH 基因介绍:Acts as an E3 ubiquitin-protein ligase which accepts ubiquitin from an E2 ubiquitin-conjugating enzyme in the form of a thioester and then directly transfers the ubiquitin to targeted substrates (PubMed:14602072, PubMed:17028573, PubMed:16387660, PubMed:18718448, PubMed:18718449, PubMed:11046148, PubMed:19592251, PubMed:19116316, PubMed:19881509, PubMed:20491914, PubMed:20392206, PubMed:20068034, PubMed:23146885, PubMed:24790097, PubMed:25631046). Catalyzes 'Lys-29'-, 'Lys-48'- and 'Lys-63'-linked ubiquitin conjugation (PubMed:17028573, PubMed:18718448, PubMed:19131965, PubMed:19881509). Involved in the control of inflammatory signaling pathways (PubMed:19131965). Essential component of a ubiquitin-editing protein complex, comprising also TNFAIP3, TAX1BP1 and RNF11, that ensures the transient nature of inflammatory signaling pathways (PubMed:19131965). Promotes the association of the complex after TNF stimulation (PubMed:19131965). Once the complex is formed, TNFAIP3 deubiquitinates 'Lys-63' polyubiquitin chains on RIPK1 and catalyzes the formation of 'Lys-48'-polyubiquitin chains (PubMed:19131965). This leads to RIPK1 proteasomal degradation and consequently termination of the TNF- or LPS-mediated activation of NFKB1 (PubMed:19131965). Ubiquitinates RIPK2 by 'Lys-63'-linked conjugation and influences NOD2-dependent signal transduction pathways (PubMed:19592251). Regulates the transcriptional activity of several transcription factors, and probably plays an important role in the regulation of immune response (PubMed:18718448, PubMed:20491914). Ubiquitinates NFE2 by 'Lys-63' linkages and is implicated in the control of the development of hematopoietic lineages (PubMed:18718448). Mediates JUN ubiquitination and degradation (By similarity). Mediates JUNB ubiquitination and degradation (PubMed:16387660). Critical regulator of type 2 helper T (Th2) cell cytokine production by inducing JUNB ubiquitination and degradation (By similarity). Involved in the negative regulation of MAVS-dependent cellular antiviral responses (PubMed:19881509). Ubiquitinates MAVS through 'Lys-48'-linked conjugation resulting in MAVS proteasomal degradation (PubMed:19881509). Following ligand stimulation, regulates sorting of Wnt receptor FZD4 to the degradative endocytic pathway probably by modulating PI42KA activity (PubMed:23146885). Ubiquitinates PI4K2A and negatively regulates its catalytic activity (PubMed:23146885). Ubiquitinates chemokine receptor CXCR4 and regulates sorting of CXCR4 to the degradative endocytic pathway following ligand stimulation by ubiquitinating endosomal sorting complex required for transport ESCRT-0 components HGS and STAM (PubMed:14602072, PubMed:23146885). Targets DTX1 for lysosomal degradation and controls NOTCH1 degradation, in the absence of ligand, through 'Lys-29'-linked polyubiquitination (PubMed:17028573, PubMed:18628966, PubMed:23886940). Ubiquitinates SNX9 (PubMed:20491914). Ubiquitinates MAP3K7 through 'Lys-48'-linked conjugation (By similarity). Involved in the regulation of apoptosis and reactive oxygen species levels through the ubiquitination and proteasomal degradation of TXNIP (PubMed:20068034). Mediates the antiapoptotic activity of epidermal growth factor through the ubiquitination and proteasomal degradation of p15 BID (PubMed:20392206). Ubiquitinates BRAT1 and this ubiquitination is enhanced in the presence of NDFIP1 (PubMed:25631046). Inhibits the replication of influenza A virus (IAV) via ubiquitination of IAV matrix protein 1 (M1) through 'Lys-48'-linked conjugation resulting in M1 proteasomal degradation (PubMed:30328013).

细胞生长培养基:McCoy’s 5A+10% FBS+1% P/S

细胞培养条件:37℃,5% CO2 的培养箱,1/3 到 1/4 传代

细胞倍增时间:~25-48 hours

细胞支原体检测结果:阴性

细胞开发路径:采用CRISPR-RNP方法生成稳定KO Cell Pool;Sanger 测序结果显示KO Cell Pool敲除效率>70%

细胞应用:高敲除效率的基因敲除细胞池(KO Cell Pool),特别适用于初步功能分析、复杂疾病模型的开发、精准药物筛选以及广泛的基因发现研究。

技术文档
没有您想要的资料?去索要
返回顶部